Hyqvia® (immune globulin infusion 10% [human] with recombinant human hyaluronidase) – New orphan indication
January 16, 2024 - Takeda announced the FDA approval of Hyqvia (immune globulin infusion 10% [human] with recombinant human hyaluronidase), for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment in adults.
Top